Coagulation biomarkers for ischemic stroke

[1]  E. Berényi,et al.  Low α2-Plasmin Inhibitor Antigen Levels on Admission Are Associated With More Severe Stroke and Unfavorable Outcomes in Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis , 2022, Frontiers in Cardiovascular Medicine.

[2]  A. Demchuk,et al.  Correlation of von Willebrand factor and platelets with acute ischemic stroke etiology and revascularization outcome: an immunohistochemical study , 2022, Journal of NeuroInterventional Surgery.

[3]  W. Ouwehand,et al.  Platelet surface receptor glycoprotein VI-dimer is overexpressed in stroke: The Glycoprotein VI in Stroke (GYPSIE) study results , 2022, PloS one.

[4]  S. Wiedmann,et al.  Feasibility of platelet marker analysis in ischemic stroke patients and their association with one-year outcome. A pilot project within a subsample of the Stroke Induced Cardiac Failure in Mice and Men (SICFAIL) cohort study , 2021, Platelets.

[5]  Hao Li,et al.  Baseline or 90-day fibrinogen levels and long-term outcomes after ischemic stroke or TIA: Results from the China national stroke registry Ⅲ. , 2021, Atherosclerosis.

[6]  W. Brinjikji,et al.  Studying Stroke Thrombus Composition After Thrombectomy: What Can We Learn? , 2021, Stroke.

[7]  V. Howard,et al.  Multiple Blood Biomarkers and Stroke Risk in Atrial Fibrillation: The REGARDS Study , 2021, Journal of the American Heart Association.

[8]  Shiliang Zhang,et al.  A Systematic Review of the Predictive Value of Plasma D-Dimer Levels for Predicting Stroke Outcome , 2021, Frontiers in Neurology.

[9]  H. ten Cate,et al.  Thrombin generation is associated with ischemic stroke at a young age. , 2021, Thrombosis research.

[10]  R. Ariëns,et al.  Thrombus Composition and Efficacy of Thrombolysis and Thrombectomy in Acute Ischemic Stroke , 2021, Stroke.

[11]  N. Abbas,et al.  D-dimer Level is Correlated with Prognosis, Infarct Size, and NIHSS in Acute Ischemic Stroke Patients* , 2021, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[12]  C. Ward‐Caviness,et al.  A Mendelian randomization of γ' and total fibrinogen levels in relation to venous thromboembolism and ischemic stroke. , 2020, Blood.

[13]  Elżbieta Papuga-Szela,et al.  Chronic Kidney Disease and Its Impact on a Prothrombotic State in Patients with Atrial Fibrillation , 2020, Journal of clinical medicine.

[14]  Q. Dong,et al.  The Value of ADAMTS13 in Predicting Clinical Outcomes in Patients With Acute Ischemic Stroke Receiving Thrombolysis , 2020, Frontiers in Neurology.

[15]  C. Zimmer,et al.  Thrombus NET content is associated with clinical outcome in stroke and myocardial infarction , 2020, Neurology.

[16]  M. Endres,et al.  Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke , 2019, Journal of thrombosis and haemostasis : JTH.

[17]  V. Feigin,et al.  World Stroke Organization (WSO): Global Stroke Fact Sheet 2019 , 2019, International journal of stroke : official journal of the International Stroke Society.

[18]  L. Desender,et al.  Structural analysis of ischemic stroke thrombi: histological indications for therapy resistance , 2019, Haematologica.

[19]  Liyi You,et al.  The association of high D-dimer level with high risk of ischemic stroke in nonvalvular atrial fibrillation patients , 2018, Medicine.

[20]  T. Aiba,et al.  Elevated Plasma D-Dimer Level Is Associated With Short-Term Risk of Ischemic Stroke in Patients With Acute Heart Failure , 2018, Stroke.

[21]  T. Beasley,et al.  Factor VIII in Acute Cerebral Ischemia Pilot Study: Biomarker in Patients With Large Vessel Occlusion? , 2018, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[22]  B. Kissela,et al.  Factor VIII, Protein C and Cardiovascular Disease Risk: The REasons for Geographic and Racial Differences in Stroke Study (REGARDS) , 2018, Thrombosis and Haemostasis.

[23]  H. Lanfermann,et al.  ADAMTS-13 Activity Predicts Outcome in Acute Ischaemic Stroke Patients Undergoing Endovascular Treatment , 2018, Thrombosis and Haemostasis.

[24]  J. Michel,et al.  Thrombus Neutrophil Extracellular Traps Content Impair tPA-Induced Thrombolysis in Acute Ischemic Stroke , 2018, Stroke.

[25]  C. Jern,et al.  Fibrinogen concentrations predict long‐term cognitive outcome in young ischemic stroke patients , 2018, Research and practice in thrombosis and haemostasis.

[26]  E. Berényi,et al.  Elevated Factor VIII and von Willebrand Factor Levels Predict Unfavorable Outcome in Stroke Patients Treated with Intravenous Thrombolysis , 2018, Front. Neurol..

[27]  J. Tembl,et al.  Neutrophil extracellular traps are increased in patients with acute ischemic stroke: prognostic significance , 2017, Thrombosis and Haemostasis.

[28]  E. Berényi,et al.  Low thrombin generation predicts poor prognosis in ischemic stroke patients after thrombolysis , 2017, PloS one.

[29]  M. Krizmaric,et al.  Clinical role of von Willebrand factor in acute ischemic stroke , 2017, Wiener klinische Wochenschrift.

[30]  M. Niewada,et al.  Fibrin clot characteristics in acute ischaemic stroke patients treated with thrombolysis: the impact on clinical outcome , 2017, Thrombosis and Haemostasis.

[31]  J. Montaner,et al.  Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome , 2016, Cerebrovascular Diseases.

[32]  A. Demchuk,et al.  Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials , 2016, The Lancet.

[33]  A. Hofman,et al.  Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. , 2015, Blood.

[34]  Mohsen Naghavi,et al.  Stroke Prevalence, Mortality and Disability-Adjusted Life Years in Adults Aged 20-64 Years in 1990-2013: Data from the Global Burden of Disease 2013 Study , 2015, Neuroepidemiology.

[35]  A. Bryer,et al.  High Levels of von Willebrand Factor and Low Levels of its Cleaving Protease, ADAMTS13, are Associated with Stroke in Young HIV-Infected Patients , 2015, International journal of stroke : official journal of the International Stroke Society.

[36]  T. Cai,et al.  Association of inflammatory and hemostatic markers with stroke and thromboembolic events in atrial fibrillation: a systematic review and meta-analysis. , 2015, The Canadian journal of cardiology.

[37]  S. Martin-Schild,et al.  Factoring in Factor VIII With Acute Ischemic Stroke , 2015, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[38]  P. Nichelli,et al.  Fibrinogen decrease after intravenous thrombolysis in ischemic stroke patients is a risk factor for intracerebral hemorrhage. , 2015, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[39]  Yun-Jiu Cheng,et al.  Risk of Thromboembolic Events in Atrial Fibrillation With Chronic Kidney Disease , 2015, Stroke.

[40]  P. Sandercock,et al.  Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository , 2014 .

[41]  A. Członkowska,et al.  Routine serum C‐reactive protein and stroke outcome after intravenous thrombolysis , 2014, Acta neurologica Scandinavica.

[42]  G. Lip,et al.  The Association of CHA2DS2-VASc Score and Blood Biomarkers with Ischemic Stroke Outcomes: The Belgrade Stroke Study , 2014, PloS one.

[43]  P. Heuschmann,et al.  Von Willebrand Factor Regulation in Patients with Acute and Chronic Cerebrovascular Disease: A Pilot, Case–Control Study , 2014, PloS one.

[44]  J. Huntington.  Natural inhibitors of thrombin , 2014, Thrombosis and Haemostasis.

[45]  Weixian Chen,et al.  Plasminogen activator inhibitor-1 4G/5G polymorphism and ischemic stroke risk: a meta-analysis in Chinese population , 2014, The International journal of neuroscience.

[46]  B. Kim,et al.  Ischemic Stroke Subtype Classification: An Asian Viewpoint , 2014, Journal of stroke.

[47]  M. Rosenqvist,et al.  Thrombin generation in acute cardioembolic and non-cardioembolic ischemic stroke , 2013, Scandinavian journal of clinical and laboratory investigation.

[48]  E. Nagel,et al.  Plasma levels of soluble glycoprotein VI (sGPVI) are associated with ischemic stroke , 2013, Platelets.

[49]  Lasek-Bal Anetta,et al.  Elevated factor VIII level and stroke in patients without traditional risk factors associated with cardiovascular diseases , 2013, Neuropsychiatric Disease and Treatment.

[50]  B. Engelmann,et al.  Thrombosis as an intravascular effector of innate immunity , 2012, Nature Reviews Immunology.

[51]  Guo-Yuan Yang,et al.  Cocktail Blood Biomarkers: Prediction of Clinical Outcomes in Patients with Acute Ischemic Stroke , 2012, European Neurology.

[52]  Z. Koncz,et al.  Factor XIII, clot structure, thrombosis. , 2012, Thrombosis research.

[53]  B. Nieswandt,et al.  Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke , 2011, Journal of thrombosis and haemostasis : JTH.

[54]  K. Yamagishi,et al.  C-reactive protein levels and risk of stroke and its subtype in Japanese: The Circulatory Risk in Communities Study (CIRCS). , 2011, Atherosclerosis.

[55]  J. Dartigues,et al.  Increased Thrombin Generation Is Associated With Acute Ischemic Stroke but Not With Coronary Heart Disease in the Elderly: The Three-City Cohort Study , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[56]  A. Hofman,et al.  High von Willebrand Factor Levels Increase the Risk of Stroke: The Rotterdam Study , 2010, Stroke.

[57]  E. Kremmer,et al.  Expression of platelet glycoprotein VI is associated with transient ischemic attack and stroke , 2010, European journal of neurology.

[58]  E. Stępień,et al.  Altered Fibrin Clot Structure/Function in Patients With Cryptogenic Ischemic Stroke , 2009, Stroke.

[59]  S. Corrao,et al.  Immuno-inflammatory and thrombotic/fibrinolytic variables associated with acute ischemic stroke diagnosis. , 2009, Atherosclerosis.

[60]  G. Lowe,et al.  Relative Value of Inflammatory, Hemostatic, and Rheological Factors for Incident Myocardial Infarction and Stroke: The Edinburgh Artery Study , 2007, Circulation.

[61]  C. Molina,et al.  Poststroke C-Reactive Protein Is a Powerful Prognostic Tool Among Candidates for Thrombolysis , 2006, Stroke.

[62]  H Tunstall-Pedoe,et al.  Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. , 2005, JAMA.

[63]  F. Leebeek,et al.  High functional levels of thrombin‐activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke , 2005, Journal of thrombosis and haemostasis : JTH.

[64]  Jian Wang,et al.  Association between platelet activation and fibrinolysis in acute stroke patients , 2005, Neuroscience Letters.

[65]  Farzaneh A. Sorond,et al.  Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis , 2005, The Lancet Neurology.

[66]  O. Anlar,et al.  Hemostatic markers and platelet aggregation factors as predictive markers for type of stroke and neurological disability following cerebral infarction , 2005, Journal of Clinical Neuroscience.

[67]  J. Arenillas,et al.  Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator , 2004, Thrombosis and Haemostasis.

[68]  P. Tonali,et al.  Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke patients , 2004, Neurological Sciences.

[69]  J. Martí-Fàbregas,et al.  Risk of Ischemic Stroke Associated With Functional Thrombin-Activatable Fibrinolysis Inhibitor Plasma Levels , 2003, Stroke.

[70]  C. Molina,et al.  Thrombin-Activable Fibrinolysis Inhibitor Levels in the Acute Phase of Ischemic Stroke , 2003, Stroke.

[71]  Natalia S. Rost,et al.  Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Study , 2001, Stroke.

[72]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[73]  M. Di Napoli,et al.  C-Reactive Protein in Ischemic Stroke: An Independent Prognostic Factor , 2001, Stroke.

[74]  F. Rosendaal,et al.  Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. , 2000, Blood.

[75]  A. Folsom,et al.  Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1999, Circulation.

[76]  J. Malm,et al.  Increased fibrinogen levels and acquired hypofibrinolysis in young adults with ischemic stroke. , 1998, Stroke.

[77]  R. Macko,et al.  Progressive intermittent claudication is associated with impaired fibrinolysis. , 1998, Journal of vascular surgery.

[78]  A. Rumley,et al.  Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[79]  W. Feinberg,et al.  Hemostatic markers in acute ischemic stroke. Association with stroke type, severity, and outcome. , 1996, Stroke.

[80]  J. Manson,et al.  Prospective study of endogenous tissue plasminogen activator and risk of stroke , 1994, The Lancet.

[81]  D. Farrell,et al.  Binding of recombinant fibrinogen mutants to platelets. , 1994, The Journal of biological chemistry.

[82]  C. Forbes,et al.  PROGNOSTIC VALUE OF BETA-THROMBOGLOBULIN IN PATIENTS WITH TRANSIENT CEREBRAL ISCHAEMIA , 1983, The Lancet.

[83]  H. Dewar,et al.  Beta-thromboglobulin in antecubital vein blood in relation to history of a stroke. , 1980, Age and ageing.

[84]  V. Čabarkapa,et al.  Fibrinolytic parameters, lipid status and lipoprotein(a) in ischemic stroke patients. , 2010, Srpski arhiv za celokupno lekarstvo.

[85]  F. Domaç,et al.  Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke. , 2007, Neurosciences.

[86]  S. Strukova.  Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation-dependent thrombosis. , 2006, Frontiers in bioscience : a journal and virtual library.

[87]  J. Gore.  Lifetime Risk for Stroke , 2006 .

[88]  S. Strukova.  Coagulation-dependent inflammation and inflammation-dependent thrombosis , 2005 .

[89]  G. Hallmans,et al.  Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. , 2000, Stroke.

[90]  T. Iwamoto,et al.  Platelet activation in the cerebral circulation in different subtypes of ischemic stroke and Binswanger's disease. , 1995, Stroke.

[91]  D. Wade,et al.  Acute stroke. , 1986, The Practitioner.